Latest Articlesddd
Arbutus Biopharma Announcement Today, June 21, 2023, Arbutus Biopharma (ABUS) announced that the first patient has …
Vera Therapeutics Vera Therapeutics (VERA) announced that Phase 2b ORIGIN clinical trial of atacicept for IgA …
Today at 2.30... Today at 2.30, the Federal Reserve Chairman Jerome Powell will speak to the …
UT Southwestern Medical Center and RenovoRx RenovoRx Inc (RNXT) announced that the University of Texas (UT) …
Amylyx Pharmaceuticals Amylyx Pharmaceuticals (AMLX) announced an update on the ongoing review of its Marketing Authorization …
Inside the Revolution In the Treatments of Untreatable Diseases We are now living a great revolution …
Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals (RETA) announced a setback of its chronic kidney disease …
Intercept Pharmaceuticals Intercept Pharmaceuticals Inc (ICPT) is a biopharmaceutical company focused on the development and commercialization …
Prostate Cancer Prostate cancer is the most common type of cancer found in men, accounting for …
Celldex Therapeutics Announcement Celldex Therapeutics (CLDX) announced today preclinical data from its CDX-622 bispecific antibody with …
Longeveron in the NEWS On May 9, 2023, Longeveron (LGVN) announced new long-term follow-up data from …
CureVac B.V. CureVac (CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) …
Gilead Sciences CHMP Adopted Positive Opinion for Hepcludex® Today, May 4, 2023, Gilead Sciences (GILD) acknowledged …
May 01, 2023 (GLOBE NEWSWIRE) –Today, Intellia Therapeutics (NTLA) released its 2023 Corporate Responsibility report. The …
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results On April 28, 2023, ImmunoGen (IMGN) reviewed …
Vertex Pharmaceuticals ORKAMBI Receives Positive CHMP Opinion Today, April 27, Vertex Pharmaceuticals (VRTX) announced that the …
Atea Pharmaceuticals Receives Fast Track Designation for Bemnifosbuvir Atea Pharmaceuticals (AVIR) announced that the U.S. FDA …
Apellis Pharmaceuticals Validation for Pegcetacoplan Apellis Pharmaceuticals (APLS) announced the receival of validation of its marketing applications …
Important News from CymaBay Therapeutics Primary Biliary Cholangitis Today, April 21, 2023, CymaBay Therapeutics (CBAY) announced that …
From Novartis on April 20, 2023 The ALITHIOS open-label extension study demonstrated that continuous treatment with …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
